目的 分析恩替卡韦与阿德福韦酯治疗乙型病毒性肝炎失代偿性肝硬化患者临床疗效.方法 选取温州市中心医院100例乙型病毒性肝炎失代偿性肝硬化患者为研究对象(2015年2月~2016年10月),随机分为对照组和实验组,各50例.对照组给予阿德福韦酯治疗,实验组进行恩替卡韦与阿德福韦酯治疗.比较分析2组患者相关临床症状比较.结果 治疗后,实验组ALT水平为(46.20±3.21)U/L,AST水平为(52.40±3.90)U/L.对照组ALT水平为(70.43±10.90)U/L,AST水平为(70.33±9.19)U/L,2组患者比较差异具有统计学意义(P<0.05).实验组患者HBV-DNA转阴率为76.0%显著高于对照组58.0%,差异具有统计学意义(P<0.05).2组患者HBeAg转阴率分别为22.0%与24.0%,差异无统计学意义.结论 恩替卡韦与阿德福韦酯治疗乙型病毒性肝炎失代偿性肝硬化患者临床疗效较为理想,能够显著改善患者肝功能,改善临床症状,安全性高.%Objective To investigate the clinical efficacy of entecavir and adefovir dipivoxil in the treatment of decompensated cirrhosis with hepatitis B virus. Methods 100 cases of decompensated cirrhosis of hepatitis B in our hospital (February 2015 to October 2016) were randomly divided into control group and experimental group, each with 50 cases. The control group was treated with adefovir dipivoxil, and the experimental group was treated with entecavir and adefovir dipivoxil. The clinical symptoms of the two groups were compared and analyzed. Results After treatment, the level of ALT in the experimental group was (46.20±3.21) U/L, and the level of AST was (52.40±3.90) U/L.The level of ALT in the control group was (70.43±10.90) U/L, and the level of AST was (70.33±9.19)U/L, and the two groups had statistical significance (P＜0.05). The negative rate of HBV-DNA in the experimental group was 76.0%, which was significantly higher than that in the control group (58.0%), and there was statistical difference (P＜0.05). The negative rate of HBeAg in the two groups was 22.0% and 24.0% respectively, and there was no significantrndifference. Conclusion Entecavir and adefovir dipivoxil in the treatment of hepatitis B liver cirrhosis patients clinical effect is ideal,can significantly improve the liver function, improve clinical symptoms, high safety, has clinical significance.
展开▼
